References
- Tremmel M, Gerdtham UG, Nilsson PM, et al. Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health. 2017 Apr 19;14(4):435.
- Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev. 2018 Apr 1;39(2):79–132.
- Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008 Feb 16;371(9612):569–578.
- Kitahara CM, Platz EA, Freeman LE, et al. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):464–472.
- Sciacca L, Vigneri R, Tumminia A, et al. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):808–815.
- Matrone A, Ferrari F, Santini F, et al. Obesity as a risk factor for thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2020 Oct;27(5):358–363.
- Polyzos SA, Kita M, Avramidis A. Thyroid nodules - stepwise diagnosis and management. Hormones (Athens). 2007 Apr-Jun;6(2):101–119.
- Davies L, Ouellette M, Hunter M, et al. The increasing incidence of small thyroid cancers: where are the cases coming from? Laryngoscope. 2010 Dec;120(12):2446–2451.
- Tumminia A, Vinciguerra F, Parisi M, et al. Adipose tissue, obesity and adiponectin: role in endocrine cancer risk. Int J Mol Sci. 2019 Jun 12;20(12). 10.3390/ijms20122863.
- Carbone F, La Rocca C, Matarese G. Immunological functions of leptin and adiponectin. Biochimie. 2012 Oct;94(10):2082–2088.
- Ray A, Cleary MP. The potential role of leptin in tumor invasion and metastasis. Cytokine Growth Factor Rev. 2017 Dec;38:80–97.
- Avgerinos KI, Spyrou N, Mantzoros CS, et al. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019 Mar;92:121–135.
- Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer. 2014 Nov;14(11):709–721.
- Marcello MA, Cunha LL, Batista FA, et al. Obesity and thyroid cancer. Endocr Relat Cancer. 2014 Oct;21(5):T255–71.
- Hwang Y, Lee KE, Park YJ, et al. Annual average changes in adult obesity as a risk factor for papillary thyroid cancer: a large-scale case-control study. Medicine (Baltimore). 2016 Mar;95(9):e2893.
- Han CY. Roles of reactive oxygen species on insulin resistance in adipose tissue. Diabetes Metab J. 2016 Aug;40(4):272–279.
- Pazaitou-Panayiotou K, Polyzos SA, Mantzoros CS. Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms. Obes Rev. 2013 Dec;14(12):1006–1022.
- Pappa T, Alevizaki M. Obesity and thyroid cancer: a clinical update. Thyroid: official j American Thyroid Ass. 2014 Feb;24((2):)190–199.
- Knudsen N, Laurberg P, Rasmussen LB, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab. 2005 Jul;90(7):4019–4024.
- de Moura Souza A, Sichieri R. Association between serum TSH concentration within the normal range and adiposity. Eur J Endocrinol/Eur Fed Endocr Soc. 2011 Jul;165(1):11–15.
- Santini F, Marzullo P, Rotondi M, et al. Mechanisms in endocrinology: the crosstalk between thyroid gland and adipose tissue: signal integration in health and disease. Eur J Endocrinol/Eur Fed Endocr Soc. 2014 Oct;171(4):R137–52.
- Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases [Research Support, Non-U.S Gov’t]. J Clin Endocrinol Metabol. 2005 Jan;90(1):124–127.
- Basolo A, Poma AM, Giannini R, et al. Histological pattern and gene expression profiling of thyroid tissue in subjects with obesity. J Endocrinol Invest. 2021 Aug;44(1):15.
- Boelaert K. The association between serum TSH concentration and thyroid cancer. Endocr Relat Cancer. 2009 Dec;16(4):1065–1072.
- Fiore E, Serum VP. TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab. 2012 Apr;97(4):1134–1145.
- Kitahara CM, Platz EA, Park Y, et al. Body fat distribution, weight change during adulthood, and thyroid cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer J Inter du Cancer. 2012 Mar 15;130(6):1411–1419.
- Matrone A, Ceccarini G, Beghini M, et al. Potential impact of BMI on the aggressiveness of presentation and clinical outcome of differentiated thyroid cancer. J Clin Endocrinol Metab. 2020 Apr 1;105(4):e1124–e1134.
- McLeod DS, Watters KF, Carpenter AD, et al. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab. 2012 Aug;97(8):2682–2692.
- Almquist M, Johansen D, Björge T, et al. Metabolic factors and risk of thyroid cancer in the metabolic syndrome and cancer project (Me-Can). Cancer Causes Control. 2011 May;22(5):743–751.
- Guo S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms. J Endocrinol. 2014 Feb;220(2):T1–T23.
- Malaguarnera R, Frasca F, Garozzo A, et al. Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab. 2011 Mar;96(3):766–774.
- Rega-Kaun G, Kaun C, Wojta J. More than a simple storage organ: adipose tissue as a source of adipokines involved in cardiovascular disease. Thromb Haemost. 2013 Oct;110(4):641–650.
- Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994 Dec 1;372(6505):425–432.
- Zhao J, Wen J, Wang S, et al. Association between adipokines and thyroid carcinoma: a meta-analysis of case-control studies. BMC Cancer. 2020 Aug 20;20(1):788.
- Hu X, Juneja SC, Maihle NJ, et al. Leptin–a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst. 2002 Nov 20;94(22):1704–1711.
- Martínez-Sánchez N. There and back again: leptin actions in white adipose tissue. Int J Mol Sci. 2020;21(17):6039.
- Brown JE, Dunmore SJ. Leptin decreases apoptosis and alters BCL-2: bax ratio in clonal rodent pancreatic beta-cells. Diabetes Metab Res Rev. 2007 Sep;23(6):497–502.
- Kim WG, Park JW, Willingham MC, et al. Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model. Endocrinology. 2013 Aug;154(8):2936–2947.
- Cheng SP, Liu CL, Hsu YC, et al. Regulation of leptin receptor expression in human papillary thyroid cancer cells. Biomed Pharmacother. 2012 Sep;66(6):469–473.
- Uddin S, Bavi P, Siraj AK, et al. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocr Relat Cancer. 2010 Mar;17(1):191–202.
- Nigro E, Orlandella FM, Polito R, et al. Adiponectin and leptin exert antagonizing effects on proliferation and motility of papillary thyroid cancer cell lines. J Physiol Biochem. 2021 May;77(2):237–248.
- Cheng SP, Yin PH, Chang YC, et al. Differential roles of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep. 2010 Jun;23(6):1721–1727.
- Celano M, Maggisano V, Lepore SM, et al. Expression of leptin receptor and effects of leptin on papillary thyroid carcinoma cells. Int J Endocrinol. 2019;2019:5031696.
- Dossus L, Franceschi S, Biessy C, et al. Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: the EPIC study. Int J Cancer J Inter du Cancer. 2018 Apr 1;142(7):1332–1342.
- Luo L, Liu M. Adipose tissue in control of metabolism. J Endocrinol. 2016 Dec;231(3):R77–r99.
- Kajimura S. Adipose tissue in 2016: advances in the understanding of adipose tissue biology. Nat Rev Endocrinol. 2017 Feb;13(2):69–70.
- Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006 Oct;6(10):772–783.
- Matsubara M, Namioka K, Katayose S. Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur J Endocrinol/Eur Fed Endocr Soc. 2003 Jun;148(6):657–662.
- Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003 Aug;26(8):2442–2450.
- Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, et al. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metab. 2011 Dec;96(12):E2023–8.
- Mele C, Samà MT, Bisoffi AA, et al. Circulating adipokines and metabolic setting in differentiated thyroid cancer. Endocr Connect. 2019 Jul;8(7):997–1006.
- Warakomski J, Romuk E, Jarząb B, et al. Concentrations of selected adipokines, interleukin-6, and vitamin d in patients with papillary thyroid carcinoma in respect to thyroid cancer stages. Int J Endocrinol. 2018;2018:4921803.
- Pazaitou-Panayiotou K, Panagiotou G, Polyzos SA, et al. Serum adiponectin and insulin-like growth factor 1 in predominantly female patients with thyroid cancer: association with the histologic characteristics of the Tumor. Endocr Pract. 2016 Jan;22(1):68–75.
- Dieudonne MN, Bussiere M, Dos Santos E, et al. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2006 Jun 23;345(1):271–279.
- Zhou Y, Yang Y, Zhou T, et al. Adiponectin and thyroid cancer: insight into the association between adiponectin and obesity. Aging Dis. 2021 Apr;12(2):597–613.
- Aust G, Hofmann A, Laue S, et al. Differential regulation of granulocyte-macrophage colony-stimulating factor mRNA and protein expression in human thyrocytes and thyroid-derived fibroblasts by interleukin-1 alpha and tumor necrosis factor-alpha. J Endocrinol. 1996 Nov;151(2):277–285.
- Jana B, Kozłowska A, Andronowska A, et al. The effect of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 beta and IL-6 on chorioamnion secretion of prostaglandins (PG)F 2 alpha and E2 in pigs. Reprod Biol. 2008 Mar;8(1):57–68.
- Wang H, Han X, Wittchen ES, et al. TNF-α mediates choroidal neovascularization by upregulating VEGF expression in RPE through ROS-dependent β-catenin activation. Mol Vis. 2016;22:116–128.
- Mingomataj EC, Bakiri AH. Regulator versus effector paradigm: interleukin-10 as indicator of the switching response. Clin Rev Allergy Immunol. 2016 Feb;50(1):97–113.
- Provatopoulou X, Georgiadou D, Sergentanis TN, et al. Interleukins as markers of inflammation in malignant and benign thyroid disease. Inflammation Res. 2014 Aug;63(8):667–674.
- Zivancevic-Simonovic S, Mihaljevic O, Majstorovic I, et al. Cytokine production in patients with papillary thyroid cancer and associated autoimmune Hashimoto thyroiditis. Cancer Immunol Immunother. 2015 Aug;64(8):1011–1019.
- Linkov F, Ferris RL, Yurkovetsky Z, et al. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics Clin Appl. 2008 Oct 10;2(12):1575–1585.
- Li CL, Dionigi G, Zhao YS, et al. Influence of body mass index on the clinicopathological features of 13,995 papillary thyroid tumors. J Endocrinol Invest. 2020 Mar;43: 1283–1299.
- Organization WH. WHO expert committee on physical status: the use and interpretation of anthropometry (1993: Geneva, Switzerland) & World Health Organization. (1995) Physical status: the use of and interpretation of anthropometry, report of a WHO expert committee. 1995.
- Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004 Jan 10;363(9403): 157–163.
- Schmid D, Ricci C, Behrens G, et al. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes Rev. 2015 Dec;16(12):1042–1054.
- CM K, Pfeiffer RM, Sosa JA, et al. **Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995-2015). J National Cancer Inst. 2020 Aug 1;112((8):):810–817.
- Shin A, Cho S, Jang D, et al. Body mass index and thyroid cancer risk: a pooled analysis of half a million men and women in the Asia Cohort Consortium. Thyroid. 2022 Jan 11;32(3):306–314.
- Han JM, Kim TY, Jeon MJ, et al. Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol/Eur Fed Endocr Soc. 2013 Jun;168(6):879–886.
- Rinaldi S, Lise M, Clavel-Chapelon F, et al. Body size and risk of differentiated thyroid carcinomas: findings from the EPIC study. Int j cancer du cancer. 2012 Sep 15;;131((6):):E1004–14.
- Kitahara CM, McCullough ML, Franceschi S, et al. Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies. Thyroid. 2016 Feb;26(2):306–318.
- Rotondi M, Castagna MG, Cappelli C, et al. Obesity does not modify the risk of differentiated thyroid cancer in a cytological series of thyroid nodules. Eur Thyroid J. 2016 Jul;5(2):125–131.
- Ahmadi S, Pappa T, Kang AS, et al. Point of care measurement of body mass index and thyroid nodule malignancy risk assessment. Front Endocrinol (Lausanne). 2022;13:824226.
- Kitahara CM, Gamborg M, Berrington de Gonzalez A, et al. Childhood height and body mass index were associated with risk of adult thyroid cancer in a large cohort study. Cancer res. 2014 Jan 1;74(1):235–242.
- Paes JE, Hua K, Nagy R, et al. The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. J Clin Endocrinol Metab. 2010 Sep;95(9):4244–4250.
- Chung YS, Lee JH, Lee YD. Is body mass index relevant to prognosis of papillary thyroid carcinoma? A clinicopathological cohort study. Surg Today. 2017 Apr;47(4):506–512.
- Gasior-Perczak D, Palyga I, Szymonek M, et al. The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer. PloS one. 2018;13(10):e0204668.
- Grani G, Lamartina L, Montesano T, et al. Lack of association between obesity and aggressiveness of differentiated thyroid cancer. J Endocrinol Invest. 2019 Jan;42(1):85–90.
- ST R, Pandeya N, Neale RE, et al., Obesity is associated with BRAF(V600E)-mutated thyroid cancer. Thyroid: off journal of American Thyroid Association. 2020 Oct;;30((10):): 1518–1527.
- Shi RL, Qu N, Liao T, et al. Relationship of body mass index with BRAF (V600E) mutation in papillary thyroid cancer. Tumour Biol. 2016 Jun;37(6):8383–8390.
- Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study [Research Support, Non-U.S. Gov’t]. J Clin Endocrinol Metab. 2008 Oct;93(10):3943–3949.
- Scheffel RS, Dora JM, Maia AL. BRAF mutations in thyroid cancer. Curr Opin Oncol. 2022 Jan 1;34(1):9–18.
- Kim HJ, Kim NK, Choi JH, et al. Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin Endocrinol (Oxf). 2013 Jan;78(1):134–140.
- Dieringer P, Klass EM, Caine B, et al. Associations between body mass and papillary thyroid cancer stage and tumor size: a population-based study. J Cancer Res Clin Oncol. 2015 Jan;141(1):93–98.
- Harari A, Endo B, Nishimoto S, et al. Risk of advanced papillary thyroid cancer in obese patients. Arch Surg. 2012 Sep;147(9):805–811.
- Zhao S, Jia X, Fan X, et al. Association of obesity with the clinicopathological features of thyroid cancer in a large, operative population: a retrospective case-control study. Medicine (Baltimore). 2019 Dec;98(50):e18213.
- Tresallet C, Seman M, Tissier F, et al. The incidence of papillary thyroid carcinoma and outcomes in operative patients according to their body mass indices. Surgery. 2014 Nov;156(5):1145–1152.
- Kim SH, Park HS, Kim KH, et al. Correlation between obesity and clinicopathological factors in patients with papillary thyroid cancer. Surg Today. 2015 Jun;45(6):723–729.
- Feng JW, Yang XH, Wu BQ, et al. Influence of body mass index on the clinicopathologic features of papillary thyroid carcinoma. Ann Otol Rhinol Laryngol. 2019 Jul;128(7):625–632.
- Kaliszewski K, Diakowska D, Rzeszutko M, et al. Obesity and Overweight Are Associated with Minimal Extrathyroidal Extension, Multifocality and Bilaterality of Papillary Thyroid Cancer. J Clin Med. 2021;10(5):970.
- Kim KN, Hwang Y, Kim KH, et al. Adolescent overweight and obesity and the risk of papillary thyroid cancer in adulthood: a large-scale case-control study. Sci Rep. 2020 Mar 19;10(1):5000.
- Wu YY, Cheng SP, Chiou PY, et al. Association between subjective symptoms and obesity and postoperative recurrence in differentiated thyroid cancer: a matched-pair analysis. Sci Rep. 2020 Feb 28;10(1):3679.
- Pasquali R, Casanueva F, Haluzik M, et al. European Society of Endocrinology clinical practice guideline: endocrine work-up in obesity. Eur J Endocrinol/Eur Fed Endocr Soc. 2020 Jan;182(1):G1–g32.